ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
化工社オープンプロジェクト:[email protected]AIアクセス:llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.7.8
  1. ホーム
  2. /化合物

Unii-5R78837D4A

HCID 71435
ノート反応
基本情報概要名称と識別子物性化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
38270-90-5
標準SMILES
[89Sr+2].[Cl-].[Cl-]
InChIKey
AHBGXTDRMVNFER-FCHARDOESA-L
分子式
Cl2Sr
平均分子量
159.81 g/mol
単同位体質量
158.845156

概要

Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stages of the disease. It is usually presented mainly in patients with prostatic and breast cancer, as well as in cancer of lung, bladder and thyroid. There has been some cases of apparent tumor regression which has given it a potential tumoricidal effect.

名称と識別子

優先名称
Unii-5R78837D4A
IUPAC
strontium-89(2+) dichloride

名称と別名

UNII-5R78837D4AMetastron (TN)Strontium chloride Sr 89 [USAN:USP]Strontium chloride Sr 89 (USP)Strontium chloride ((sup 89)SrCl2)D02006

データベース識別子

CAS
38270-90-5
PubChem CID
71435

物性

構造計算による物性

極性表面積
0 Ų
水素結合供与体数
0
水素結合受容体数
2
回転可能結合数
0
重原子数
3
形式電荷
0
複雑度
2.8

実験および物理化学的性質

Solubility10.9-22.6 mg/ml
Boiling Point100ºC
Melting Point0ºC

化学と産業

薬理情報

Protein Binding · 1 件

In some studies performed in polluted water, it was showed that strontium is able to bind to plasma proteins. In human plasma studies, it has been shown a possible recovery of 45-60% of administered strontium by ultrafiltration, while other studies confirm a protein binding of 30-40%.

Pharmacodynamics · 1 件

Metastatic bone lesions are zones of high bone mineral turnover. Thus, there is a constant need of calcium supply for the development of the malignancy. Strontium chloride 89 is a divalent ion, similar to calcium, therefore it is taken up by sites of active osteogenesis. This relieves bone metastatic-driven pain withouth generating important side effects and it also presents a very little radioprotection concern. Once combined with external beam radiotherapy, strontium chloride 89 can emit β particules with a maximum range in tissue of 6-8mm. This radiation is capable to reduce new bone metastases and produces an analgesic role.

Mechanism of Action · 1 件

Strontium chloride 89, a similar to calcium divalent ion, concentrates in areas of increased osteogenesis, by being taken up into the inorganic matter of the bone. Strontium chloride 89 presents a 10-fold higher affinity for metastatic bone. Some reports indicate that after Strontium chloride 89 is incorporated into the osteoid matrix adjascently to the metastatic cells, it emits β-rays getting even to 1.3-64Gy. Thus, there is a possible tumoricidal effect driven by the radiation selectively emited by strontium chloride 89 into metastatic bones.

Biological Half-LifeStrontium chloride 89 presents a half-life of 50.5 days.
Metabolism/Metabolites · 1 件

Strontium can interact with components than normally bind to calcium, including hydroxyapatite (main component of mineralized bone), calcium-binding or calcium-transport proteins. It can form complexes with different inorganic anions like carbonate, citrate, phosphate, carboxylic acid or lactate.

Absorption, Distribution and Excretion · 4 件

Following intravenous injection, strontium chloride 89 behaves like its calcium analog. It clears rapidly from the blood stream and selectively gets localized on the bone mineral, preferentially in zones of osteogenesis, where it can stay retained for about 14 days.

関連反応

0 件
反応記録を作成

現在のフィルター条件では反応記録がありません。

化合物ノート

読み込み中…

このページの内容基本情報概要名称と識別子物性化学と産業関連反応化合物ノート

The elimination is done mainly by urinary excretion greatly in the two first days after injection. The rest of the elimination route is found in faeces. The percentage of urinary excretion may vary depending on the presence of bone lesions. The presence of strontium chloride 89 in faeces suggests an absorption into the gastrointestinal tract either by the bile or from the plasma.

There have been several studies regarding the pharmacokinetics of different administration routes of strontium chloride 89. The values are different but it ranges between 40-67L.

Strontium chloride 89 is mainly cleared by urine on a 3:1 ratio compared with fecal excretion. The total drug clearance can be slow, giving it a long half-life.